Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias.
Blockade of the Kv1.5 ion channel is a potentially atrial-selective avenue for the treatment of atrial fibrillation and atrial flutter. The development and biological evaluation of a series of thiazolidine-based blockers of Kv1.5 is described.
Jackson
Chris M
CM
Procter and Gamble Pharmaceuticals, The Mason Business Center, 8700 Mason-Montgomery Road, Mason, OH 45040, USA.
Blass
Benjamin
B
Coburn
Keith
K
Djandjighian
Laurent
L
Fadayel
Gina
G
Fluxe
Andrew J
AJ
Hodson
Steven J
SJ
Janusz
John M
JM
Murawsky
Michael
M
Ridgeway
James M
JM
White
Ronald E
RE
Wu
Shengde
S
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000737:chemistry* / Q000494:pharmacology*; D001281:Atrial Fibrillation / Q000188:drug therapy; D001282:Atrial Flutter / Q000188:drug therapy; D006801:Humans; D051666:Kv1.5 Potassium Channel / Q000037:antagonists & inhibitors*; D026902:Potassium Channel Blockers / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D051381:Rats; D053778:Thiazolidines / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*
D000889:Anti-Arrhythmia Agents; C496981:KCNA5 protein, human; D051666:Kv1.5 Potassium Channel; D026902:Potassium Channel Blockers; D053778:Thiazolidines